About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
(C) 2024 MINKABU THE INFONOID, Inc.

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.(2395) Financial Results

2395
TSE Prime
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
1,678
JPY
+74
(+4.61%)
Dec 23, 3:30 pm JST
10.71
USD
Dec 23, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
Current Period Guidance
Annual
Result
Guidance History
Growth Rate
Profitability
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2021 15,110 2,529 3,645 3,661 88.0 20 May 10, 2021 J-GAAP
Mar, 2022 17,748 4,195 7,078 7,127 171.2 40 May 6, 2022 J-GAAP
Mar, 2023 25,090 5,245 9,194 6,060 145.6 50 May 8, 2023 J-GAAP
Mar, 2024 26,450 4,162 7,015 5,531 132.9 50 May 8, 2024 J-GAAP
Mar, 2025 Guidance 29,835 2,350 5,345 3,920 94.2 50 May 8, 2024 J-GAAP
YoY +12.8% -43.5% -23.8% -29.1% -29.1%
All-Time High
Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS
Record 26,450 5,245 9,194 7,127 171.2
Fiscal Year Mar, 2024 Mar, 2023 Mar, 2023 Mar, 2022 Mar, 2022
Second Half
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2021 9,787 2,226 4,549 3,624 87.1 40 May 6, 2022 J-GAAP
Oct - Mar, 2022 14,742 2,932 3,266 1,641 39.4 30 May 8, 2023 J-GAAP
Oct - Mar, 2023 14,566 1,813 3,259 2,565 61.6 30 May 8, 2024 J-GAAP
Oct - Mar, 2024 Guidance 17,327 2,270 3,516 2,589 62.2 30 Nov 6, 2024 J-GAAP
YoY +19.0% +25.2% +7.9% +0.9% +0.9%
Cash Flow
Annual
Fiscal Year Operating Profit Fee Cash Flow Operating Cash Flow Investing Cash Flow Financial Cash Flow Cash & Equivalents Cash Ratio Accounting Standards
Mar, 2022 4,195 1,684 5,952 -4,268 -4,911 4,548 11.57 J-GAAP
Mar, 2023 5,245 -1,926 4,004 -5,930 6,266 9,197 16.07 J-GAAP
Mar, 2024 4,162 -4,801 2,106 -6,907 5,318 10,274 13.46 J-GAAP
Actual Performance and Financial Trends
Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2022 10,348 2,313 5,928 4,419 106.2 64.5 Oct 31, 2022 J-GAAP
Apr - Sep, 2023 11,884 2,349 3,756 2,966 71.2 53.5 Nov 7, 2023 J-GAAP
Apr - Sep, 2024 12,508 80 1,829 1,331 32.0 34.2 Nov 6, 2024 J-GAAP
YoY +5.3% -96.6% -51.3% -55.1% -55.1%
Quarterly Results
Result
Growth Rate
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2022 6,023 1,470 952 -68 -1.6 24.4 Jan 31, 2023 J-GAAP
Jan - Mar, 2023 8,719 1,462 2,314 1,709 41.1 16.8 May 8, 2023 J-GAAP
Apr - Jun, 2023 5,804 1,227 1,877 1,373 33.0 21.1 Aug 2, 2023 J-GAAP
Jul - Sep, 2023 6,080 1,122 1,879 1,593 38.3 18.5 Nov 7, 2023 J-GAAP
Oct - Dec, 2023 6,100 186 1,128 828 19.9 3.0 Feb 2, 2024 J-GAAP
Jan - Mar, 2024 8,466 1,627 2,131 1,737 41.7 19.2 May 8, 2024 J-GAAP
Apr - Jun, 2024 5,549 -145 342 122 2.9 -2.6 Aug 6, 2024 J-GAAP
Jul - Sep, 2024 6,959 225 1,487 1,209 29.0 3.2 Nov 6, 2024 J-GAAP
YoY +14.5% -79.9% -20.9% -24.1% -24.1%
All-Time High Quarterly Results
Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS
Record 8,719 1,627 3,156 2,475 59.5
Fiscal Year Mar, 2023 Mar, 2024 Sep, 2022 Sep, 2022 Sep, 2022
Key Balance Sheet Figures
Fiscal Year BPS Equity Ratio Total Asset Equity Retained Earnings Interest-Bearing Debt Ratio Announce Accounting Standards
Mar, 2022 469.85 49.8 39,312 19,561 10,196 0.47 May 6, 2022 J-GAAP
Mar, 2023 629.60 45.8 57,242 26,211 13,766 0.72 May 8, 2023 J-GAAP
Mar, 2024 819.42 44.7 76,302 34,114 17,215 0.77 May 8, 2024 J-GAAP
Apr - Sep, 2024 875.03 40.9 88,983 36,429 17,297 0.96 Nov 6, 2024 J-GAAP